Home > References and Included Studies -...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Tsertsvadze A, Yazdi F, Fink HA, et al. Diagnosis and Treatment of Erectile Dysfunction. Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 May. (Evidence Reports/Technology Assessments, No. 171.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

References and Included Studies

1.
Anonymous. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993 Jul 7;270(1):83–90. [PubMed: 8510302]
2.
Feldman HA, Goldstein I, Hatzichristou DG. et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994 Jan;151(1):54–61. [PubMed: 8254833]
3.
Bella A, Lue T. Male sexual dysfunction. In: Tanagho E, editors. Smith's General Urology, 17th ed. New York: Lange/McGraw Hill; 2008. p. 589–610.
4.
Lin C, Lin G, Lue T. Cyclic nucleotide signaling in cavernous smooth muscle. J Sex Med. 2005;2(4):478–91. [PubMed: 16422842]
5.
Shabsigh R, Kaufman JM, Steidle C. et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004 Aug;172(2):658–63. [PubMed: 15247755]
6.
Musicki B, Burnett A. eNOS function and dysfunction in the penis. Exp Biol Med. 2006;231(2):154–65. [PubMed: 16446491]
7.
Burnett AL. Role of nitric oxide in the physiology of erection. Biol Reprod. 1995;52(3):485–9. [PubMed: 7756443]
8.
Lue TF. Erectile dysfunction. N Engl J Med. 2000;342(24):1802–13. [PubMed: 10853004]
9.
Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995 Jan;75(1):191–236. [PubMed: 7831397]
10.
Jin L, Burnett AL. RhoA/Rho-kinase in erectile tissue: mechanisms of disease and therapeutic insights. Clin Sci (Lond) 2006 Feb;110(2):153–65. [PubMed: 16411892]
11.
Rehman J, Benet A, Minsky LS. et al. Results of surgical treatment for abnormal penile curvature: Peyronie's disease and congenital deviation by modified Nesbit plication (tunical shaving and plication) J Urol. 1997 Apr;157(4):1288–91. [PubMed: 9120923]
12.
Brock G. Erectile dysfunction update education forum summary. Can J Urol. 2000;8:1416–8. [PubMed: 11799970]
13.
Fazio L, Brock G. Erectile dysfunction: Management update. CMAJ: Canadian Medical Association Journal. 2004;170(9):1429–37. [PMC free article: PMC395819] [PubMed: 15111479]
14.
Montague DK, Jarow JP, Broderick GA. et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol. 2005 Jul;174(1):230–9. [PubMed: 15947645]
15.
Rosen RC, Riley A, Wagner G. et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997 Jun;49(6):822–30. [PubMed: 9187685]
16.
Rosen RC, Cappelleri JC, Smith MD. et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11(6):319–26. [PubMed: 10637462]
17.
Althof SE, Corty EW, Levine SB. et al. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology. 1999 Apr;53(4):793–9. [PubMed: 10197859]
18.
Rosen RC, Cappelleri JC, Gendrano N III. The International Index of Erectile Function (IIEF): a state-of-the-science review. [Review] [63 refs] Int J Impot Res. 2002 Aug;14(4):226–44. [PubMed: 12152111]
19.
Burnett AL, Johns DG, Kriegsfeld LJ. et al. Ejaculatory abnormalities in mice with targeted disruption of the gene for heme oxygenase-2. Nat Med. 1998 Jan;4(1):84–7. [PubMed: 9427611]
20.
Johnson AR III, Jarow JP. Is routine endocrine testing of impotent men necessary? J Urol. 1992 Jun;147(6):1542–3. [PubMed: 1593685]
21.
Miller TA. Diagnostic evaluation of erectile dysfunction. Am Fam Physician. 2000 Jan 1;61(1):95–10. [PubMed: 10643952]
22.
Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999 Jul;84(1):50–6. [PubMed: 10444124]
23.
Johannes CB, Araujo AB, Feldman HA. et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study.[see comment] J Urol. 2000 Feb;163(2):460–3. [PubMed: 10647654]
24.
Virag R. Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology. 1999 Dec;54(6):1073–7. [PubMed: 10604711]
25.
Kendirci M, Trost L, Sikka SC. et al. The effect of vascular risk factors on penile vascular status in men with erectile dysfunction. J Urol. 2007 Dec;178(6):2516–20. [PubMed: 17937942]
26.
Rosen RC, Leiblum SR, Spector IP. Psychologically based treatment for male erectile disorder: a cognitive-interpersonal model. J Sex Marital Ther. 1994;20(2):67–85. [PubMed: 8035472]
27.
Esposito K, Giugliano F, Di PC. et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial.[see comment] JAMA. 2004 Jun 23;291(24):2978–84. [PubMed: 15213209]
28.
Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. [Review] [219 refs] J Urol. 1996 Mar;155(3):802–15. [PubMed: 8583582]
29.
Wessells H, Joyce GF, Wise M. et al. Erectile dysfunction. J Urol. 2007 May;177(5):1675–81. [PubMed: 17437781]
30.
Simmons M, Montague DK. Penile prosthesis implantation: past, present and future. Int J Impot Res 2008 Apr 3; [PubMed: 18385678]
31.
Anonymous. Bayer Annual Report. 2005.
32.
Anonymous. Eli Lilly Annual Report. 2005.
33.
Wessells H. Pfizer Annual Report. 2007.
34.
Carson C. Long-term use of sildenafil. Expert Opin Pharmacother. 2003;4(3):397–405. [PubMed: 12614192]
35.
Hanson-Divers C, Jackson SE, Lue TF. et al. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol. 1998 May;159(5):1541–7. [PubMed: 9554350]
36.
Carson C, Giuliano F, Goldstein I. et al. The ‘effectiveness’ scale—therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report. [Review] [7 refs] Int J Impot Res. 2004 Jun;16(3):207–13. [PubMed: 15164088]
37.
Noldus J, Huland H. [Erectile dysfunction and hypogonadism. Is routine endocrine screening necessary?] Urologe A. 1994 Jan;33(1):73–5. [PubMed: 8146936]
38.
Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy.[see comment]. [Review] [16 refs] J Urol. 1997 Nov;158(5):1764–7. [PubMed: 9334596]
39.
Wespes E, Amar E, Hatzichristou D. et al. EAU Guidelines on Erectile Dysfunction: An Update. Eur Urol. 2006;49(5):806–15. [PubMed: 16530932]
40.
Miller TA. Diagnostic evaluation of erectile dysfunction. Am Fam Physician. 2000 Jan 1;61(1):95–10. [PubMed: 10643952]
41.
Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav. 1983 Feb;12(1):59–66. [PubMed: 6838355]
42.
Morelli A, Filippi S, Mancina R. et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004 May;145(5):2253–63. [PubMed: 14764637]
43.
Aversa A, Isidori AM, De Martino MU. et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf) 2000 Oct;53(4):517–22. [PubMed: 11012578]
44.
Lue TF, Broderick G. Evaluation and nonsurgical management of erectile dysfunction and priapism. In: Walsh P, Retik A, Vaughan E, editors. Campbell's Urology, 7th ed Philadelphia, PA: Saunders; 1998. p. 1181–214.
45.
Kropman RF, Nijeholt AA, Zwartendijk J. Experiences with the Surgitek Art-1000 penile tumescence and rigidity monitor, and comparison with the RigiScan. J Urol. 1991 Jul;146(1):43–5. [PubMed: 2056603]
46.
Whiting P, Rutjes AW, Reitsma JB. et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003 Nov 10;3:25. [PMC free article: PMC305345] [PubMed: 14606960]
47.
Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996 Feb;17(1):1–12. [PubMed: 8721797]
48.
Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet. 2002 Feb 16;359(9306):614–8. [PubMed: 11867132]
49.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–88. [PubMed: 3802833]
50.
Higgins JP, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 6;327(7414):557–60. [PMC free article: PMC192859] [PubMed: 12958120]
51.
Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2(2):121–45. [PubMed: 8261254]
52.
Deeks JJ, Higgins JP, Altman DG. Analysing and presenting results. In: Cochrane Handbook for Systematic Reviews of Interventions, 4.2.6 2006. 8 p. 97–165.
53.
Egger M, Davey SG, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 Sep 13;315(7109):629–34. [PMC free article: PMC2127453] [PubMed: 9310563]
54.
Lau J, Ioannidis JP, Terrin N. et al. The case of the misleading funnel plot. BMJ. 2006 Sep 16;333(7568):597–600. [PMC free article: PMC1570006] [PubMed: 16974018]
55.
Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001 Oct;54(10):1046–55. [PubMed: 11576817]
56.
Netto Junior NR, Claro JA. The importance of hyperprolactinemia in impotence. Rev Paul Med. 1993 Nov;111(6):454–5. [PubMed: 8052792]
57.
Citron J, Ettinger B, Rubinoff H. et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J Urol. 1996;155(Feb.):529–33. [PubMed: 8558653]
58.
Hatzichristou D, Hatzimouratidis K, Bekas M. et al. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol. 2002;168(2):615–20. [PubMed: 12131320]
59.
Martinez-Jabaloyas JM, Queipo-Zaragoza A, Pastor-Hernandez F. et al. Testosterone levels in men with erectile dysfunction. BJU Int. 2006 Jun;97(6):1278–83. [PubMed: 16686726]
60.
Acar D, Cayan S, Bozlu M. et al. Is routine hormonal measurement necessary in initial evaluation of men with erectile dysfunction? Arch Androl. 2004 Jul;50(4):247–53. [PubMed: 15277002]
61.
Earle CM, Stuckey BG. Biochemical screening in the assessment of erectile dysfunction: what tests decide future therapy? Urology. 2003 Oct;62(4):727–31. [PubMed: 14550452]
62.
Rhoden EL, Teloken C, Mafessoni R. et al. Is there any relation between serum levels of total testosterone and the severity of erectile dysfunction? Int J Impot Res. 2002 Jun;14(3):167–71. [PubMed: 12058243]
63.
Bunch TJ, Abraham D, Wang S. et al. Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction. Aging Male. 2002 Mar;5(1):38–46. [PubMed: 12040974]
64.
Fahmy AK, Mitra S, Blacklock AR. et al. Is the measurement of serum testosterone routinely indicated in men with erectile dysfunction? BJU Int. 1999 Sep;84(4):482–4. [PubMed: 10468766]
65.
Akpunonu BE, Mutgi AB, Federman DJ. et al. Routine prolactin measurement is not necessary in the initial evaluation of male impotence. J Gen Intern Med. 1994 Jun;9(6):336–8. [PubMed: 8077999]
66.
Drinka PJ, Voeks S, Bauwens S. et al. Sensitivity and positive predictive value of clinical signs of hypogonadism in elderly men. South Med J. 1993 Nov;86(11):1264–5. [PubMed: 8235781]
67.
El-Sakka AI, Hassoba HM, Sayed HM. et al. Pattern of endocrinal changes in patients with sexual dysfunction. J Sex Med. 2005;2(4):551–8. [PubMed: 16422853]
68.
Tsujimura A, Matsumiya K, Miyagawa Y. et al. Comparative study on evaluation methods for serum testosterone level for PADAM diagnosis. Int J Impot Res. 2005;17(3):259–63. [PubMed: 15616608]
69.
Guay AT, Bansal S, Hodge MB. Possible hypothalamic impotence: Male counterpart to hypothalamic amenorrhea? Urology. 1991;38(4):317–22. [PubMed: 1755138]
70.
Forsberg L, Gustavii B, Hojerback T. et al. One hundred impotent men. Scand J Urol Nephrol. 1990;24(2):83–7. [PubMed: 2356457]
71.
Reyes-Vallejo L, Lazarou S, Morgentaler A. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone. J Sex Med. 2006 Nov 6;4(6):1757–62. [PubMed: 17087806]
72.
El-Sakka AI, Hassoba HM. Age related testosterone depletion in patients with erectile dysfunction. J Urol. 2006 Dec;176(6 Pt 1):2589–93. [PubMed: 17085165]
73.
Low WY, Khoo EM, Tan HM. et al. Depression, hormonal status and erectile dysfunction in the aging male: results from a community study in Malaysia. J Mens Health Gend. 2006;3(3):263–70.
74.
Guay A, Jacobson J. The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction. J Sex Med. 2007 Jul;4(4 Pt 1):1046–55. [PubMed: 17627749]
75.
Zohdy W, Kamal EE, Ibrahim Y. Androgen deficiency and abnormal penile duplex parameters in obese men with erectile dysfunction. J Sex Med. 2007 May;4(3):797–808. [PubMed: 17498110]
76.
Rhoden EL, Teloken C, Sogari PR. et al. The relationship of serum testosterone to erectile function in normal aging men. J Urol. 2002 Apr;167(4):1745–8. [PubMed: 11912401]
77.
Aversa A, Isidori AM, Spera G. et al. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003 May;58(5):632–8. [PubMed: 12699447]
78.
Palmer JS, Kaplan WE, Firlit CF. Erectile dysfunction in patients with spina bifida is a treatable condition. J Urol. 2000 Sep;164(3 Pt 2):958–61. [PubMed: 10958716]
79.
Seidman SN, Roose SP, Menza MA. et al. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry. 2001 Oct;158(10):1623–30. [PubMed: 11578994]
80.
Kongkanand A, Ratana-Olarn K, Ruangdilokrat S. et al. The efficacy and safety of oral sildenafil in Thai men with erectile dysfunction: a randomized, double-blind, placebo controlled, flexible-dose study. J Med Assoc Thai. 2003 Mar;86(3):195–205. [PubMed: 12757058]
81.
Stuckey BG, Jadzinsky MN, Murphy LJ. et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care. 2003 Feb;26(2):279–84. [PubMed: 12547849]
82.
Choi HK, Ahn TY, Kim JJ. et al. A double-blind, randomised- placebo, controlled, parallel group, multicentre, flexible-dose escalation study to assess the efficacy and safety of sildenafil administered as required to male outpatients with erectile dysfunction in Korea. Int J Impot Res. 2003 Apr;15(2):80–6. [PubMed: 12789384]
83.
Levinson IP, Khalaf IM, Shaeer KZ. et al. Efficacy and safety of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in Egypt and South Africa. Int J Impot Res. 2003 Apr;15(Suppl 1):25–9. [PubMed: 12825106]
84.
DeBusk RF, Pepine CJ, Glasser DB. et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol. 2004 Jan 15;93(2):147–53. [PubMed: 14715338]
85.
Boolell M, Gepi-Attee S, Gingell JC. et al. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol. 1996 Aug;78(2):257–61. [PubMed: 8813924]
86.
Goldstein I, Lue TF, Padma-Nathan H. et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998 May 14;338(20):1397–404. [PubMed: 9580646]
87.
Tan HM, Moh CL, Mendoza JB. et al. Asian sildenafil efficacy and safety study (ASSESS-1): a double-blind, placebo-controlled, flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. The Assess-1 Study Group. Urology. 2000 Oct 1;56(4):635–40. [PubMed: 11018621]
88.
Meuleman E, Cuzin B, Opsomer RJ. et al. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int. 2001 Jan;87(1):75–81. [PubMed: 11121996]
89.
Eardley I, Morgan R, Dinsmore W. et al. Efficacy and safety of sildenafil citrate in the treatment of men with mild to moderate erectile dysfunction. Br J Psychiatry. 2001 Apr;178(Apr.):325–30. [PubMed: 11282811]
90.
Young JM, Bennett C, Gilhooly P. et al. Efficacy and safety of sildenafil citrate (Viagra) in black and Hispanic American men. Urology. 2002 Sep;60(2 Suppl 2):39–48. [PubMed: 12414332]
91.
Nurnberg HG, Hensley PL, Gelenberg AJ. et al. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA. 2003 Jan 1;289(1):56–64. [PubMed: 12503977]
92.
Incrocci L, Hop WC, Slob AK. Efficacy of sildenafil in an open-label study as a continuation of a double-blind study in the treatment of erectile dysfunction after radiotherapy for prostate cancer. Urology. 2003 Jul;62(1):116–20. [PubMed: 12837434]
93.
Price DE, Gingell JC, Gepi-Attee S. et al. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med. 1998 Oct;15(10):821–5. [PubMed: 9796881]
94.
Rendell MS, Rajfer J, Wicker PA. et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA. 1999 Feb 3;281(5):421–6. [PubMed: 9952201]
95.
Christiansen E, Guirguis WR, Cox D. et al. Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int J Impot Res. 2000 Jun;12(3):177–82. [PubMed: 11045912]
96.
Olsson AM, Speakman MJ, Dinsmore WW. et al. Sildenafil citrate (Viagra) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed aetiology. Int J Clin Pract. 2000 Nov;54(9):561–6. [PubMed: 11220982]
97.
Chen KK, Hsieh JT, Huang ST. et al. ASSESS-3: a randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan. Int J Impot Res. 2001 Aug;13(4):221–9. [PubMed: 11494079]
98.
Boulton AJ, Selam JL, Sweeney M. et al. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia. 2001 Oct;44(10):1296–301. [PubMed: 11692178]
99.
Hussain IF, Brady CM, Swinn MJ. et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001 Sep;71(3):371–4. [PMC free article: PMC1737541] [PubMed: 11511713]
100.
Lewis R, Bennett CJ, Borkon WD. et al. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology. 2001 May;57(5):960–5. [PubMed: 11337303]
101.
Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. J Diabetes Complications. 2004 Jul;18(4):205–10. [PubMed: 15207837]
102.
Webster LJ, Michelakis ED, Davis T. et al. Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch Intern Med. 2004 Mar 8;164(5):514–20. [PubMed: 15006828]
103.
Eardley I, Mirone V, Montorsi F. et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int. 2005 Dec;96(9):1323–32. [PubMed: 16287454]
104.
Cavallini G, Modenini F, Vitali G. et al. Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology. 2005 Nov;66(5):1080–5. [PubMed: 16286128]
105.
Diamond LE, Earle DC, Garcia WD. et al. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005 Apr;65(4):755–9. [PubMed: 15833522]
106.
Melnik T, Abdo CH. Psychogenic erectile dysfunction: comparative study of three therapeutic approaches. J Sex Med. 2005 May;31(3):243–55. [PubMed: 16020142]
107.
Fowler CJ, Miller JR, Sharief MK. et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005 May;76(5):700–5. [PMC free article: PMC1739638] [PubMed: 15834030]
108.
Mahon A, Sidhu PS, Muir G. et al. The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients. Am J Kidney Dis. 2005 Feb;45(2):381–7. [PubMed: 15685517]
109.
Katz SD, Parker JD, Glasser DB. et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol. 2005 Jan 1;95(1):36–42. [PubMed: 15619391]
110.
Abdel-Naser MB, Imam A, Wollina U. Sildenafil citrate significantly improves nocturnal penile erections in sildenafil non-responding patients with psychogenic erectile dysfunction. Int J Impot Res. 2004 Dec;16(6):552–6. [PubMed: 15116063]
111.
Deveci S, Peskircioglu L, Aygun C. et al. Sublingual sildenafil in the treatment of erectile dysfunction: faster onset of action with less dose. Int J Urol. 2004 Nov;11(11):989–92. [PubMed: 15509203]
112.
Gentile V, Vicini P, Prigiotti G. et al. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin. 2004 Sep;20(9):1377–84. [PubMed: 15383186]
113.
Rosen RC, Seidman SN, Menza MA. et al. Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. Int J Impot Res. 2004 Aug;16(4):334–40. [PubMed: 14961048]
114.
Perimenis P, Markou S, Gyftopoulos K. et al. Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study. Andrologia. 2004 Jun;36(3):106–10. [PubMed: 15206909]
115.
Tignol J, Furlan PM, Gomez-Beneyto M. et al. Efficacy of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in remission from depression. Int Clin Psychopharmacol. 2004 Jul;19(4):191–9. [PubMed: 15201565]
116.
Perimenis P, Karkoulias K, Markou S. et al. Erectile dysfunction in men with obstructive sleep apnea syndrome: a randomized study of the efficacy of sildenafil and continuous positive airway pressure. Int J Impot Res. 2004 Jun;16(3):256–60. [PubMed: 15057257]
117.
Eardley I, Wright P, MacDonagh R. et al. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int. 2004 Jun;93(9):1271–5. [PubMed: 15180621]
118.
von Keitz A, Rajfer J, Segal S. et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol. 2004;45(4):499–507. [PubMed: 15041116]
119.
Mancini M, Raina R, Agarwal A. et al. Sildenafil citrate vs intracavernous alprostadil for patients with arteriogenic erectile dysfunction: a randomised placebo controlled study. Int J Impot Res. 2004 Feb;16(1):8–12. [PubMed: 14963465]
120.
Perimenis P, Gyftopoulos K, Giannitsas K. et al. A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. Int J Impot Res. 2004 Feb;16(1):2–7. [PubMed: 14963464]
121.
Govier F, Potempa AJ, Kaufman J. et al. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Eur Urol. 2003 Nov;25(11):2709–23. [PubMed: 14693299]
122.
Padma-Nathan H, Stecher VJ, Sweeney M. et al. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology. 2003 Sep;62(3):400–3. [PubMed: 12946731]
123.
Seibel I, Poli de Figueiredo CE, Teloken C. et al. Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. J Am Soc Nephrol. 2002 Nov;13(11):2770–5. [PubMed: 12397048]
124.
Ugarte F, Hurtado-Coll A. Comparison of the efficacy and safety of sildenafil citrate (Viagra) and oral phentolamine for the treatment of erectile dysfunction. Int J Impot Res. 2002 Aug;14(Suppl 2):48–53. [PubMed: 12161768]
125.
Gomez F, Davila H, Costa A. et al. Efficacy and safety of oral sildenafil citrate (Viagra) in the treatment of male erectile dysfunction in Colombia, Ecuador, and Venezuela: a double-blind, multicenter, placebo-controlled study. Int J Impot Res. 2002 Aug;14(Suppl 2):42–7. [PubMed: 12161767]
126.
Becher E, Tejada NA, Gomez R. et al. Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study. Int J Impot Res. 2002 Aug;14(Suppl 2):33–41. [PubMed: 12161766]
127.
Glina S, Bertero E, Claro J. et al. Efficacy and safety of flexible-dose oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction in Brazilian and Mexican men. Int J Impot Res. 2002 Aug;14(Suppl 2):27–32. [PubMed: 12161765]
128.
Lindsey I, George B, Kettlewell M. et al. Randomized, double-blind, placebo-controlled trial of sildenafil (Viagra) for erectile dysfunction after rectal excision for cancer and inflammatory bowel disease. Dis Colon Rectum. 2002 Jun;45(6):727–32. [PubMed: 12072621]
129.
Lim PH, Ng FC, Cheng CW. et al. Clinical safety profile of sildenafil in Singaporean men with erectile dysfunction: pre-marketing experience (ASSESS-I evaluation) J Int Med Res. 2002 Mar;30(2):137–43. [PubMed: 12025521]
130.
Eardley I, Ellis P, Boolell M. et al. Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol. 2002;53(Suppl 1):61–5. [PMC free article: PMC1874251] [PubMed: 11879261]
131.
Incrocci L, Koper PC, Hop WC. et al. Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study. Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1190–5. [PubMed: 11728676]
132.
Choppin A, Blue DR, Hegde SS. et al. Evaluation of oral ro70-0004/003, an alpha1A-adrenoceptor antagonist, in the treatment of male erectile dysfunction. Int J Impot Res. 2001 Jun;13(3):157–61. [PubMed: 11525314]
133.
Olsson AM, Persson CA. Swedish Sildenafil Investigators Group. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int J Clin Pract. 2001 Apr;55(3):171–6. [PubMed: 11351770]
134.
Montorsi F, Maga T, Strambi LF. et al. Sildenafil taken at bedtime significantly increases nocturnal erections: results of a placebo-controlled study. Urology. 2000 Dec 20;56(6):906–11. [PubMed: 11113728]
135.
Cappelleri JC, Siegel RL, Osterloh IH. et al. Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function. Urology. 2000 Sep 1;56(3):477–81. [PubMed: 10962319]
136.
Palmer JS, Kaplan WE, Firlit CF. Erectile dysfunction in spina bifida is treatable. Lancet. 1999 Jul 10;354(9173):125–6. [PubMed: 10408490]
137.
Montorsi F, McDermott TE, Morgan R. et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology. 1999 May;53(5):1011–8. [PubMed: 10223498]
138.
Dinsmore WW, Hodges M, Hargreaves C. et al. Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects.[erratum appears in Urology 1999 May;53(5):1072] Urology. 1999 Apr;53(4):800–5. [PubMed: 10197860]
139.
Eardley I, Brooks J, Yates PK. et al. Sildenafil citrate (VIAGRA): an oral treatment for erectile function with activity for up to four hours' duration. Int J Clin Pract. 1999 Jun;102(Suppl Jun.):102–4. [PubMed: 10665121]
140.
Hartmann U, Meuleman EJ, Cuzin B. et al. Sildenafil citrate (VIAGRA): analysis of preferred doses in a European, six-month, double-blind, placebo-controlled, flexible dose-escalation study in patients with erectile dysfunction. Multicentre Study Group. Int J Clin Pract. 1999 Jun;102(Suppl Jun.):102–9. [PubMed: 10665119]
141.
Young J. Sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction: a 12-week, flexible-dose study to assess efficacy and safety. Int J Clin Pract. 1999 Jun;102(Suppl Jun.):6–7. [PubMed: 10665111]
142.
Padma-Nathan H, Steers WD, Wicker PA. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group. Int J Clin Pract. 1998 Sep;52(6):375–9. [PubMed: 9894373]
143.
Albuquerque DC, Miziara LJ, Saraiva JFK. et al. Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs. Int Braz J Urol. 2005;31(4):342–55. [PubMed: 16137403]
144.
Yonessi M, Saeedi M. A double-blind placebo-controlled evaluation of the effect of topical sildenafil on erectile dysfunction. J App Res. 2005;5(2):289–94.
145.
Shamloul R, Ghanem H, Fahmy I. et al. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: A pilot study. J Sex Med. 2005;2(4):559–64. [PubMed: 16422854]
146.
Gingell C, Sultana SR, Wulff MB. et al. Duration of action of sildenafil citrate in men with erectile dysfunction. J Sex Med. 2004;1(2):179–84. [PubMed: 16422972]
147.
Pickering TG, Shepherd AMM, Puddey I. et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: A randomized controlled trial. Am J Hypertens. 2004;17(12):1135–42. [PubMed: 15607620]
148.
Pavone C, Curto F, Anello G. et al. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J Urol. 2004;172(6 Pt 1):2347–9. [PubMed: 15538264]
149.
Bawa AS, Sharma DR, Singh R. et al. Efficacy and tolerability of sildenafil in Indian males with erectile dysfunction: A double-blind, randomized, placebo-controlled, crossover study. Indian J Pharmacol. 2004;36(5):317.
150.
Dunzendorfer U, Behm A, Dunzendorfer E. et al. Drug combinations in the therapy of low response to phosphodiesterase 5 inhibitors in patients with erectile dysfunction. In Vivo. 2002;16(5):345–8. [PubMed: 12494876]
151.
Glina S, Bertero E, Claro J. et al. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in Latin America. Braz J Urol. 2001;27(2):148–54.
152.
Barry MJ. Sildenafil improved sexual function in erectile dysfunction. Int J Impot Res. 1998;3(6):184.
153.
Shabsigh R. Efficacy of sildenafil citrate (VIAGRA) is not affected by aetiology of erectile dysfunction. Int J Clin Pract. 1999 Jan;102(Jun.):19–20. [PubMed: 10665116]
154.
Padma-Nathan H. Oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction: assessment of erections hard enough for sexual intercourse. Int J Clin Pract. 1999 Jan;102(Jun.):13–5. [PubMed: 10665114]
155.
Perimenis P, Karkoulias K, Konstantinopoulos A. et al. Sildenafil versus continuous positive airway pressure for erectile dysfunction in men with obstructive sleep apnea: a comparative study of their efficacy and safety and the patient's satisfaction with treatment. Asian J Androl. 2007 Mar;9(2):259–64. [PubMed: 17334593]
156.
Heiman JR, Talley DR, Bailen JL. et al. Sexual function and satisfaction in heterosexual couples when men are administered sildenafil citrate (Viagra) for erectile dysfunction: a multicentre, randomised, double-blind, placebo-controlled trial. BJOG. 2007 Apr;114(4):437–47. [PubMed: 17284249]
157.
Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J Androl. 2007 Jan;9(1):134–41. [PubMed: 17187165]
158.
Bank AJ, Kelly AS, Kaiser DR. et al. The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. Vasc Med. 2006 Nov;11(4):251–7. [PubMed: 17390549]
159.
Porst H, Behre HM, Jungwirth A. et al. Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction—an open, randomized cross-over study with flexible dosing. Eur J Med Res. 2007 Feb 26;12(2):61–7. [PubMed: 17369119]
160.
McVary KT, Monnig W, Camps JL Jr. et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007 Mar;177(3):1071–7. [PubMed: 17296414]
161.
Zinner N. Do food and dose timing affect the efficacy of sildenafil? A randomized placebo-controlled study. J Sex Med. 2007 Jan;4(1):137–44. [PubMed: 17233779]
162.
Safarinejad MR. Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study. Int J Impot Res. 2006 Nov;18(6):550–8. [PubMed: 16625231]
163.
Tolra JR, Campana JM, Ciutat LF. et al. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med. 2006 Sep;3(5):901–9. [PubMed: 16942534]
164.
Orr G, Weiser M, Polliack M. et al. Effectiveness of sildenafil in treating erectile dysfunction in PTSD patients: a double-blind, placebo-controlled crossover study. J Clin Psychopharmacol. 2006 Aug;26(4):426–30. [PubMed: 16855464]
165.
Sharma RK, Prasad N, Gupta A. et al. Treatment of erectile dysfunction with sildenafil citrate in renal allograft recipients: a randomized, double-blind, placebo-controlled, crossover trial. Am J Kidney Dis. 2006 Jul;48(1):128–33. [PubMed: 16797395]
166.
Althof SE, O'Leary MP, Cappelleri JC. et al. Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: Results from an international, multi-center, double-blind, placebo-controlled trial. J Sex Med. 2006 May;3(3):521–9. [PubMed: 16681478]
167.
Fava M, Nurnberg HG, Seidman SN. et al. Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2006 Feb;67(2):240–6. [PubMed: 16566619]
168.
Gopalakrishnan R, Jacob KS, Kuruvilla A. et al. Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. Am J Psychiatry. 2006 Mar;163(3):494–9. [PubMed: 16513872]
169.
Herrmann HC, Levine LA, Macaluso J Jr. et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med. 2006 Mar;3(2):303–8. [PubMed: 16490024]
170.
Rochira V, Balestrieri A, Madeo B. et al. Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections.[erratum appears in J Androl. 2006 May–Jun;27(3):480] J Androl. 2006 Mar;27(2):165–75. [PubMed: 16278367]
171.
O'Leary MP, Althof SE, Cappelleri JC. et al. Self-esteem, confidence and relationship satisfaction of men with erectile dysfunction treated with sildenafil citrate: a multicenter, randomized, parallel group, double-blind, placebo controlled study in the United States. J Urol. 2006 Mar;175(3 Pt 1):1058–62. [PubMed: 16469617]
172.
Viswaroop B, B A, Gopalakrishnan G. Evaluating erectile dysfunction: oral sildenafil versus intracavernosal injection of papaverine. Natl Med J India. 2005 Nov;18(6):299–301. [PubMed: 16483029]
173.
Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51(6):1717–23. [PubMed: 17258855]
174.
Salonia A. Sildenafil citrate: A safe and effective treatment for erectile dysfunction after renal transplantation? Commentary. Nature Clinical Practice Nephrology. 2007;3(2):80–1. [PubMed: 17251995]
175.
Koulikov D, Fridmans A, Chertin B. et al. Is sildenafil citrate associated with an amelioration of the symptomatology of androgen decline in the aging male? J Urol. 2007 Jun;177(6):2267–71. [PubMed: 17509338]
176.
Gray PB, Singh AB, Woodhouse LJ. et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab. 2005 Jul;90(7):3838–46. [PubMed: 15827094]
177.
Karkos CD, Wood A, Bruce IA. et al. Erectile dysfunction after open versus angioplasty aortoiliac procedures: a questionnaire survey. Vascular & Endovascular Surgery. 2004 Mar;38(2):157–65. [PubMed: 15064847]
178.
Giuliano F, Donatucci C, Montorsi F. et al. Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population of men, irrespective of age. BJU Int. 2005 Jan;95(1):110–6. [PubMed: 15638906]
179.
Hatzichristou D, Vardi Y, Papp G. et al. Effect of tadalafil on sexual timing behavior patterns in men with erectile dysfunction: integrated analysis of randomized, placebo controlled trials. J Urol. 2005 Oct;174(4 Pt 1):1356–9. [PubMed: 16145426]
180.
Mazo E, Gamidov S, Iremashvili V. The effect of vardenafil on endothelial function of brachial and cavernous arteries. Int J Impot Res. 2006 Sep;18(5):464–9. [PubMed: 16482199]
181.
Goldstein I, Young JM, Fischer J. et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003 Mar;26(3):777–83. [PubMed: 12610037]
182.
Valiquette L, Young JM, Moncada I. et al. Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2005 Oct;80(10):1291–7. [PubMed: 16212141]
183.
Nehra A, Grantmyre J, Nadel A. et al. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol. 2005 Jun;173(6):2067–71. [PubMed: 15879836]
184.
Carson CC, Hatzichristou DG, Carrier S. et al. Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial.[erratum appears in BJU Int. 2005 Aug;96(3):466] BJU Int. 2004 Dec;94(9):1301–9. [PubMed: 15610110]
185.
Porst H, Young JM, Schmidt AC. et al. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology. 2003 Sep;62(3):519–23. [PubMed: 12946758]
186.
Fisher WA, Rosen RC, Mollen M. et al. Improving the sexual quality of life of couples affected by erectile dysfunction: A double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med. 2005;2(5):699–708. [PubMed: 16422828]
187.
Brock G, Nehra A, Lipshultz LI. et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol. 2003 Oct;170(4 Pt 1):1278–83. [PubMed: 14501741]
188.
Hatzichristou DG, Aliotta P, Auerbach S. et al. Erectile response to vardenafil in men with a history of nonresponse to sildenafil: A time-from-dosing descriptive analysis. Eur Urol. 2005;27(9):1452–61. [PubMed: 16291418]
189.
Nagao K, Ishii N, Kamidono S. et al. Safety and efficacy of vardenafil in patients with erectile dysfunction: result of a bridging study in Japan. Int J Urol. 2004 Jul;11(7):515–24. [PubMed: 15242361]
190.
Stief C, Porst H, Saenz dT I. et al. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract. 2004 Mar;58(3):230–9. [PubMed: 15117088]
191.
Hatzichristou D, Montorsi F, Buvat J. et al. The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men. Eur Urol. 2004;45(5):634–41. [PubMed: 15082207]
192.
Hellstrom WJ, Gittelman M, Karlin G. et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl. 2002 Nov;23(6):763–71. [PubMed: 12399521]
193.
Stark S, Sachse R, Liedl T. et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol. 2001;40(2):181–8. [PubMed: 11528196]
194.
Porst H, Rosen R, Padma-Nathan H. et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001 Aug;13(4):192–9. [PubMed: 11494074]
195.
Klotz T, Sachse R, Heidrich A. et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol. 2001 Feb;19(1):32–9. [PubMed: 11289568]
196.
van Ahlen H, Wahle K, Kupper W. et al. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med. 2005;2(6):856–64. [PubMed: 16422810]
197.
Goldstein I, Fisher WA, Sand M. et al. Women's sexual function improves when partners are administered vardenafil for erectile dysfunction: A prospective, randomized, double-blind, placebo-controlled trial. J Sex Med. 2005;2(6):819–32. [PubMed: 16422806]
198.
Montorsi F, Padma-Nathan H, Buvat J. et al. Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: A randomized, double-blind, placebo-controlled trial. J Sex Med. 2004;1(2):168–78. [PubMed: 16422971]
199.
Rosen R, Shabsigh R, Berber M. et al. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: The depression-related improvement with vardenafil for erectile response study. Am J Psychiatry. 2006;163(1):79–87. [PubMed: 16390893]
200.
Martin-Morales A, Meijide F, Garcia N. et al. Efficacy of vardenafil and influence on self-esteem and self-confidence in patients with severe erectile dysfunction. J Sex Med. 2007 Mar;4(2):440–7. [PubMed: 17367439]
201.
Edwards D, Hackett G, Collins O. et al. Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): a randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naive men with ED and their partners. J Sex Med. 2006 Nov;3(6):1028–36. [PubMed: 17100936]
202.
Valiquette L, Montorsi F, Auerbach S. et al. First-dose success with vardenafil in men with erectile dysfunction and associated comorbidities: RELY-I. Int J Clin Pract. 2006 Nov;60(11):1378–85. [PubMed: 17073835]
203.
Porst H, Sharlip ID, Hatzichristou D. et al. Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study. Eur Urol. 2006 Nov;50(5):1086–94. [PubMed: 16820261]
204.
Ziegler D, Merfort F, Van AH. et al. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med. 2006 Sep;3(5):883–91. [PubMed: 16942532]
205.
Ishii N, Nagao K, Fujikawa K. et al. Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. Int J Urol. 2006 Aug;13(8):1066–72. [PubMed: 16903931]
206.
Demir E, Balal M, Paydas S. et al. Efficacy and safety of vardenafil in renal transplant recipients with erectile dysfunction. Transplant Proc. 2006 Jun;38(5):1379–81. [PubMed: 16797309]
207.
Hatzichristou DG, Cuzin B, Martin-Morales A. et al. Vardenafil improves satisfaction rates, depressive symptomatology, and self- confidence in a broad population of men with erectile dysfunction. J Sex Med. 2005;2(1):109–16. [PubMed: 16422913]
208.
Hellstrom WJ, Gittelman M, Karlin G. et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology. 2003 Apr;61(4 Suppl 1):8–14. [PubMed: 12657355]
209.
Hellstrom WJ, Elhilali M, Homering M. et al. Vardenafil in patients with erectile dysfunction: achieving treatment optimization. J Androl. 2005 Sep;26(5):604–9. [PubMed: 16088037]
210.
Donatucci C, Taylor T, Thibonnier M. et al. Verdenafil improves patient satisfaction with erection hardness, orgasmic function and overall sexual experience, while improving quality of life in men with erectile dysfunction. J Sex Med. 2004;1(2):185–92. [PubMed: 16422973]
211.
Shafik A, Shafik I, El-Sibai O. et al. Overactive corpus cavernosum: a novel cause of erectile dysfunction. Andrologia. 2004 Dec;36(6):378–83. [PubMed: 15541054]
212.
Dundar SO. Visual loss associated with erectile dysfunction drugs. Can J Ophthalmol. 2007 Feb;42(1):10–2. [PubMed: 17361234]
213.
Gupta S, Salimpour P, Saenz dT I. et al. A possible mechanism for alteration of human erectile function by digoxin: inhibition of corpus cavernosum sodium/potassium adenosine triphosphatase activity. J Urol. 1998 May;159(5):1529–36. [PubMed: 9554348]
214.
Mirone V, Costa P, Damber JE. et al. An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol. 2005;47(6):846–54. [PubMed: 15925082]
215.
Young JM, Feldman RA, Auerbach SM. et al. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. J Androl. 2005 May;26(3):310–8. [PubMed: 15866997]
216.
McMahon CG, Stuckey BG, Lording DW. et al. A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomised, double-blind, parallel-group, placebo-controlled study in Australian men. Int J Clin Pract. 2005 Feb;59(2):143–9. [PubMed: 15854188]
217.
Carson C, Shabsigh R, Segal S. et al. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Urology. 2005 Feb;65(2):353–9. [PubMed: 15708052]
218.
Rosano GM, Aversa A, Vitale C. et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol. 2005;47(2):214–20. [PubMed: 15661417]
219.
De Rose AF, Gallo F, Carmignani G. Evaluation of sexual activity in patients treated with tadalafil: a randomized prospective placebo-controlled trial. Int J Impot Res. 2005 Jan;17(1):76–9. [PubMed: 15510191]
220.
Eardley I, Gentile V, Austoni E. et al. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. BJU Int. 2004 Oct;94(6):871–7. [PubMed: 15476525]
221.
Staab A, Tillmann C, Forgue ST. et al. Population dose-response model for tadalafil in the treatment of male erectile dysfunction. Pharm Res. 2004 Aug;21(8):1463–70. [PubMed: 15359583]
222.
Montorsi F, Nathan HP, McCullough A. et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial.[erratum appears in J Urol. 2005 Feb;173(2):664] J Urol. 2004 Sep;172(3):1036–41. [PubMed: 15311032]
223.
Skoumal R, Chen J, Kula K. et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol. 2004;46(3):362–9. [PubMed: 15306109]
224.
Seftel AD, Wilson SK, Knapp PM. et al. The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction.[erratum appears in J Urol. 2005 Feb;173(2):664] J Urol. 2004 Aug;172(2):652–7. [PubMed: 15247754]
225.
Porst H, Padma-Nathan H, Giuliano F. et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003;62(1):121–5. [PubMed: 12837435]
226.
Saenz dT I, Anglin G, Knight JR. et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care. 2002 Dec;25(12):2159–64. [PubMed: 12453954]
227.
Carrier S, Brock GB, Pommerville PJ. et al. Efficacy and safety of oral tadalafil in the treatment of men in canada with erectile dysfunction: A randomized, double-blind, parallel, placebo-controlled clinical trial. J Sex Med. 2005;2(5):685–98. [PubMed: 16422827]
228.
McMahon C, Kloner RA, Hutter AM Jr. et al. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005;2(3):415–27. [PubMed: 16422874]
229.
Chen KK, Jiann BP, Lin JSN. et al. Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: A randomized, double-blind, parallel, placebo-controlled clinical study. J Sex Med. 2004;1(2):201–8. [PubMed: 16422975]
230.
Rosen RC, Padma-Nathan H, Shabsigh R. et al. Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: A multicenter, randomized, double-blind, placebo-controlled, at-home study. J Sex Med. 2004;1(2):193–200. [PubMed: 16422974]
231.
Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia. 2006 Apr;38(2):61–8. [PubMed: 16529577]
232.
Aversa A, Greco E, Bruzziches R. et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res. 2007 Mar;19(2):200–7. [PubMed: 16943794]
233.
McVary KT, Roehrborn CG, Kaminetsky JC. et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007 Apr;177(4):1401–7. [PubMed: 17382741]
234.
Saylan M, Khalaf I, Kadioglu A. et al. Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction. Int J Clin Pract. 2006 Jul;60(7):812–9. [PMC free article: PMC1569641] [PubMed: 16846400]
235.
Rajfer J, Aliotta PJ, Steidle CP. et al. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res. 2007 Jan;19(1):95–103. [PubMed: 16871272]
236.
Yip WC, Chiang HS, Mendoza JB. et al. Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: a randomized double-blind, parallel, placebo-controlled clinical study. Asian J Androl. 2006 Nov;8(6):685–92. [PubMed: 16855765]
237.
Guo YL, Zhu JC, Pan TM. et al. Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men. Int J Urol. 2006 Jun;13(6):721–7. [PubMed: 16834650]
238.
Nagao K, Kimoto Y, Marumo K. et al. Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study. Urology. 2006 Oct;68(4):845–51. [PubMed: 17070365]
239.
Incrocci L, Slagter C, Slob AK. et al. A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):439–44. [PubMed: 16965992]
240.
Choi HK, Kim JJ, Kim SC. et al. A randomised, double-blind, parallel, placebo-controlled study of the efficacy and safety of Tadalafil administered on-demand to men with erectile dysfunction in Korea. Taehan Pinyogikwa Hakhoe Chapchi. 2006;47(8):852–8.
241.
Dean J, Hackett GI, Gentile V. et al. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J Sex Med. 2006 Jul;3(4):650–61. [PubMed: 16839321]
242.
McMahon CG, Carson CC, Fischer CJ. et al. Tolerance to the therapeutic effect of tadalafil does not occur during 6 months of treatment: A randomized, double-blind, placebo-controlled study in men with erectile dysfunction. J Sex Med. 2006 May;3(3):504–11. [PubMed: 16681476]
243.
Carson CC. Efficacy and safety of tadalafil in men with severe erectile dysfunction in tertiary care academic centers. Curr Urol Rep. 2005 Nov;6(6):437–8. [PubMed: 16238917]
244.
Moncada I, Damber JE, Mirone V. et al. Sexual intercourse attempt patterns with two dosing regimens of tadalafil in men with erectile dysfunction: Results from the SURE study in 14 European countries. J Sex Med. 2005;2(5):668–74. [PubMed: 16422825]
245.
Costa P, Buvat J, Holmes S. et al. Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens. J Sex Med. 2006 Nov;3(6):1050–8. [PubMed: 17100938]
246.
Wespes E, Moncada I, Schmitt H. et al. The influence of age on treatment outcomes in men with erectile dysfunction treated with two regimens of tadalafil: results of the SURE study. BJU Int. 2007 Jan;99(1):121–6. [PubMed: 17227498]
247.
Buvat J, Van AH, Schmitt H. et al. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled use versus on-demand regimen evaluation (SURE) study in 14 European countries. J Sex Med. 2006 May;3(3):512–20. [PubMed: 16681477]
248.
von Keitz A, Stroberg P, Bukofzer S. et al. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction. BJU Int. 2002 Mar;89(4):409–15. [PubMed: 11872034]
249.
Gontero P, D'Antonio R, Pretti G. et al. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. Int J Impot Res. 2005 Jan;17(1):80–5. [PubMed: 15510184]
250.
Hagemann JH, Berding G, Bergh S. et al. Effects of visual sexual stimuli and apomorphine SL on cerebral activity in men with erectile dysfunction. Eur Urol. 2003 Apr;43(4):412–20. [PubMed: 12667723]
251.
Lammers PI, Rubio-Aurioles E, Castell R. et al. Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunction. Int J Impot Res. 2002;14(1):54–9. [PubMed: 11896479]
252.
Dula E, Bukofzer S, Perdok R. et al. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol. 2001;39(5):558–3. [PubMed: 11464037]
253.
Dula E, Keating W, Siami PF. et al. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group. Urology. 2000 Jul;56(1):130–5. [PubMed: 10869641]
254.
Arruda-Olson AM, Pellikka PA. Appropriate use of exercise testing prior to administration of drugs for treatment of erectile dysfunction. [Review] [47 refs] Herz. 2003 Jun;28(4):291–7. [PubMed: 12825144]
255.
Seyam R, Mohamed K, Akhras AA. et al. A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1. Int J Impot Res. 2005 Jul;17(4):346–53. [PubMed: 15772683]
256.
Gontero P, Fontana F, Bagnasacco A. et al. Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J Urol. 2003 Jun;169(6):2166–9. [PubMed: 12771740]
257.
Van der WF, Dohle GR, Van Der TJ. et al. Intracavernosal injection therapy with and without sexological counselling in men with erectile dysfunction. BJU Int. 2002 Jun;89(9):901–4. [PubMed: 12010236]
258.
Fu Q, Yao DH, Jiang YQ. A clinical comparative study on effects of intracavernous injection of sodium nitroprusside and papaverine/phentolamine in erectile dysfunction patients. Asian J Androl. 2000 Dec;2(4):301–3. [PubMed: 11202421]
259.
Baum N, Randrup E, Junot D. et al. Prostaglandin E1 versus sex therapy in the management of psychogenic erectile dysfunction. Int J Impot Res. 2000 Jun;12(3):191–4. [PubMed: 11045914]
260.
Sandhu D, Curless E, Dean J. et al. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Int J Impot Res. 1999 Apr;11(2):91–7. [PubMed: 10356669]
261.
Dinsmore WW, Gingell C, Hackett G. et al. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study. BJU Int. 1999 Feb;83(3):274–9. [PubMed: 10233493]
262.
Buvat J, Costa P, Morlier D. et al. Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. J Urol. 1998 Jan;159(1):116–9. [PubMed: 9400450]
263.
Montorsi F, Guazzoni G, Barbieri L. et al. Genital plus audiovisual sexual stimulation following intracavernous vasoactive injection versus re-dosing for erectile dysfunction—results of a prospective study. J Urol. 1998 Jan;159(1):113–5. [PubMed: 9400449]
264.
Sogari PR, Teloken C, Souto CA. Atropine role in the pharmacological erection test: study of 228 patients. J Urol. 1997 Nov;158(5):1760–3. [PubMed: 9334595]
265.
Montorsi F, Guazzoni G, Strambi LF. et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol. 1997 Oct;158(4):1408–10. [PubMed: 9302132]
266.
Bechara A, Casabe A, Cheliz G. et al. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction. J Urol. 1997 Jun;157(6):2132–4. [PubMed: 9146599]
267.
Aversa A, Rocchietti-March M, Caprio M. et al. Anxiety-induced failure in erectile response to intracorporeal prostaglandin-E1 in non-organic male impotence: a new diagnostic approach. Int J Androl. 1996 Oct;19(5):307–13. [PubMed: 8985780]
268.
Colli E, Calabro A, Gentile V. et al. Alprostadil sterile powder formulation for intracavernous treatment of erectile dysfunction. Eur Urol. 1996;29(1):59–62. [PubMed: 8821692]
269.
Godschalk M, Gheorghiu D, Katz PG. et al. Alkalization does not alleviate penile pain induced by intracavernous injection of prostaglandin E1. J Urol. 1996 Sep;156(3):999–1000. [PubMed: 8709384]
270.
Gheorghiu D, Godschalk M, Gheorghiu S. et al. Slow injection of prostaglandin E1 decreases associated penile pain. Urology. 1996 Jun;47(6):903–4. [PubMed: 8677586]
271.
Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996 Apr 4;334(14):873–7. [PubMed: 8596569]
272.
Bechara A, Casabe A, Cheliz G. et al. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses. J Urol. 1996 Mar;155(3):913–4. [PubMed: 8583605]
273.
Wegner HE, Knispel HH, Klan R. et al. Efficacy of linsidomine chlorhydrate, a direct nitric oxide donor, in the treatment of human erectile dysfunction: results of a double-blind cross over trial. Int J Impot Res. 1995 Dec;7(4):233–7. [PubMed: 8770666]
274.
Vanderschueren D, Heyrman RM, Keogh EJ. et al. A study in patients with erectile dysfunction comparing different formulations of prostaglandin E1. Alprostadil Study Group. J Urol. 1995 Nov;154(5):1744–7. [PubMed: 7563337]
275.
el-Saleh JC, Keogh EJ, Chew KK. et al. Does compression of the base of the penis improve the efficacy of intracavernosal injection of prostaglandin E1 for impotence? A randomized controlled study. Int J Impot Res. 1995 Mar;7(1):23–31. [PubMed: 7670590]
276.
Ogrinc FG, Linet OI. Evaluation of real-time RigiScan monitoring in pharmacological erection. J Urol. 1995 Oct;154(4):1356–9. [PubMed: 7658536]
277.
Kattan S. Double-blind randomized crossover study comparing intracorporeal prostaglandin E1 with combination of prostaglandin E1 and lidocaine in the treatment of organic impotence. Urology. 1995 Jun;45(6):1032–6. [PubMed: 7771004]
278.
Martinez-Pineiro L, Lopez-Tello J, onso Dorrego JM. et al. Preliminary results of a comparative study with intracavernous sodium nitroprusside and prostaglandin E1 in patients with erectile dysfunction. J Urol. 1995 May;153(5):1487–90. [PubMed: 7714974]
279.
Wegner HE, Knispel HH, Klan R. et al. Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction. Urol Int. 1994;53(4):214–6. [PubMed: 7855939]
280.
Schramek P, Plas EG, Hubner WA. et al. Intracavernous injection of prostaglandin E1 plus procaine in the treatment of erectile dysfunction. J Urol. 1994 Oct;152(4):1108–10. [PubMed: 8072075]
281.
Godschalk MF, Chen J, Katz PG. et al. Treatment of erectile failure with prostaglandin E1: a double-blind, placebo-controlled, dose-response study. J Urol. 1994 Jun;151(6):1530–2. [PubMed: 8189563]
282.
von Heyden B, Donatucci CF, Marshall GA. et al. A prostaglandin E1 dose-response study in man. J Urol. 1993 Dec;150(6):1825–8. [PubMed: 8230515]
283.
Moriel EZ, Rajfer J. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction. J Urol. 1993 May;149(5 Pt 2):1299–300. [PubMed: 8386779]
284.
Porst H. Prostaglandin E1 and the nitric oxide donor linsidomine for erectile failure: a diagnostic comparative study of 40 patients. J Urol. 1993 May;149(5 Pt 2):1280–3. [PubMed: 8479015]
285.
Costa P, Sarrazin B, Bressolle F. et al. Efficiency and side effects of intracavernous injections of moxisylyte in impotent patients: a dose-finding study versus placebo. J Urol. 1993 Feb;149(2):301–5. [PubMed: 8426406]
286.
Allen RP, Engel RM, Smolev JK. et al. Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1. J Urol. 1992 Oct;148(4):1181–3. [PubMed: 1404632]
287.
Mahmoud KZ, el Dakhli MR, Fahmi IM. et al. Comparative value of prostaglandin E1 and papaverine in treatment of erectile failure: double-blind crossover study among Egyptian patients. J Urol. 1992 Mar;147(3):623–6. [PubMed: 1538443]
288.
Kattan S, Collins JP, Mohr D. Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence. Urology. 1991 Jun;37(6):516–8. [PubMed: 2038782]
289.
Floth A, Schramek P. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone. J Urol. 1991 Jan;145(1):56–9. [PubMed: 1984099]
290.
Roy JB, Petrone RL, Said SI. A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection. J Urol. 1990 Feb;143(2):302–4. [PubMed: 2405186]
291.
Earle CM, Keogh EJ, Wisniewski ZS. et al. Prostaglandin E1 therapy for impotence, comparison with papaverine. J Urol. 1990 Jan;143(1):57–9. [PubMed: 2294263]
292.
Garceau RJ, Zhang IX, Jen L. Dose-response studies of intracavernous injection therapy with alprostadil in Asian and Australian men with erectile dysfunction. Curr Ther Res Clin Exp. 1996;57(1):50–61.
293.
Kunelius P, Lukkarinen O. Intracavernous injection test in the evaluation of patients with erectile dysfunction: a blind, cross-over placebo-controlled study between three different vasoactive agents in 30 impotent inpatients. Sexual Dysfunct. 1998;1(1):35–8.
294.
Titta M, Tavolini IM, Moro FD. et al. Sexual counseling improved erectile rehabilitation after non-nerve-sparing radical retropubic prostatectomy or cystectomy—results of a randomized prospective study. J Sex Med. 2006 Mar;3(2):267–73. [PubMed: 16490019]
295.
Wessells H, Levine N, Hadley ME. et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000 Oct;12(Suppl 4):74–9. [PubMed: 11035391]
296.
Wessells H, Gralnek D, Dorr R. et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000 Oct 1;56(4):641–6. [PubMed: 11018622]
297.
Segraves RT, Bari M, Segraves K. et al. Effect of apomorphine on penile tumescence in men with psychogenic impotence. J Urol. 1991 Jun;145(6):1174–5. [PubMed: 2033687]
298.
Rosen RC, Diamond LE, Earle DC. et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004 Apr;16(2):135–42. [PubMed: 14999221]
299.
Ekman P, Sjogren L, Englund G. et al. Optimizing the therapeutic approach of transurethral alprostadil. BJU Int. 2000 Jul;86(1):68–74. [PubMed: 10886086]
300.
Shabsigh R, Padma-Nathan H, Gittleman M. et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology. 2000 Jan;55(1):109–13. [PubMed: 10654905]
301.
Shokeir AA, Alserafi MA, Mutabagani H. Intracavernosal versus intraurethral alprostadil: a prospective randomized study. BJU Int. 1999 May;83(7):812–5. [PubMed: 10368203]
302.
Williams G, Abbou CC, Amar ET. et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br J Urol. 1998 Jun;81(6):889–94. [PubMed: 9666777]
303.
Peterson CA, Bennett AH, Hellstrom WJ. et al. Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations. J Urol. 1998;159(5):1523–7. [PubMed: 9554347]
304.
Padma-Nathan H, Hellstrom WJ, Kaiser FE. et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997 Jan 2;336(1):1–7. [PubMed: 8970933]
305.
Lazzeri M, Barbanti G, Beneforti P. et al. Intraurethrally infused capsaicin induces penile erection in humans. Scand J Urol Nephrol. 1994 Dec;28(4):409–12. [PubMed: 7886417]
306.
Padma-Nathan H, Steidle C, Salem S. et al. The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED. Int J Impot Res. 2003 Feb;15(1):10–7. [PubMed: 12605235]
307.
Cavallini G. Minoxidil versus nitroglycerin: a prospective double-blind controlled trial in transcutaneous erection facilitation for organic impotence. J Urol. 1991 Jul;146(1):50–3. [PubMed: 1905361]
308.
Claes H, Smet G, Baert L. The influence of transcutaneous nitroglycerine on nocturnal erections. J Drug Dev. 1992;4(4):229–33.
309.
Diamond LE, Earle DC, Rosen RC. et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004 Feb;16(1):51–9. [PubMed: 14963471]
310.
Foldvari M, Oguejiofor C, Afridi S. et al. Liposome encapsulated prostaglandin E1 in erectile dysfunction: correlation between in vitro delivery through foreskin and efficacy in patients. Urology. 1998 Nov;52(5):838–43. [PubMed: 9801110]
311.
Goldstein I, Payton TR, Schechter PJ. A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Urology. 2001 Feb;57(2):301–5. [PubMed: 11182341]
312.
Le Roux PJ, Naude JH. Topical vasoactive cream in the treatment of erectile failure: a prospective, randomized placebo-controlled trial. BJU Int. 1999 May;83(7):810–1. [PubMed: 10368202]
313.
Cavallini G. Minoxidil versus nitroglycerine: a prospective, double-blind, controlled trial in transcutaneous therapy for organic impotence. Int J Impot Res. 1994 Dec;6(4):205–12. [PubMed: 7795721]
314.
Gomaa A, Shalaby M, Osman M. et al. Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate. BMJ. 1996 Jun 15;312(7045):1512–5. [PMC free article: PMC2351261] [PubMed: 8646143]
315.
Gramkow J, Lendorf A, Zhu J. et al. Transcutaneous nitroglycerine in the treatment of erectile dysfunction: a placebo controlled clinical trial. Int J Impot Res. 1999 Feb;11(1):35–9. [PubMed: 10098952]
316.
Haren M, Chapman I, Coates P. et al. Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age Ageing. 2005 Mar;34(2):125–30. [PubMed: 15596419]
317.
Seftel AD, Mack RJ, Secrest AR. et al. Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. J Androl. 2004 Nov;25(6):963–72. [PubMed: 15477371]
318.
Steidle C, Schwartz S, Jacoby K. et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003 Jun;88(6):2673–81. [PubMed: 12788872]
319.
Cavallini G, Caracciolo S, Vitali G. et al. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology. 2004 Apr;63(4):641–6. [PubMed: 15072869]
320.
McNicholas TA, Dean JD, Mulder H. et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003 Jan;91(1):69–74. [PubMed: 12614254]
321.
Kunelius P, Lukkarinen O, Hannuksela ML. et al. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab. 2002 Apr;87(4):1467–72. [PubMed: 11932266]
322.
Gomaa A, Eissa M, El-Gebaley A. The effect of topically applied vasoactive agents and testosterone versus testosterone in the treatment of erectile dysfunction in aged men with low sexual interest. Int J Impot Res. 2001 Apr;13(2):93–9. [PubMed: 11426345]
323.
Clopper RR, Voorhess ML, MacGillivray MH. et al. Psychosexual behavior in hypopituitary men: A controlled comparison of gonadotropin and testosterone replacement. Psychoneuroendocrinology. 1993;18(2):149–61. [PubMed: 8493299]
324.
Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003 Mar;6(1):1–7. [PubMed: 12809074]
325.
Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000;57(2):141–7. [PubMed: 10665616]
326.
Schiavi RC, White D, Mandeli J. et al. Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Arch Sex Behav. 1997 Jun;26(3):231–41. [PubMed: 9146812]
327.
Wang C, Swerdloff RS, Iranmanesh A. et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000 Aug;85(8):2839–53. [PubMed: 10946892]
328.
Seidman SN, Roose SP. The sexual effects of testosterone replacement in depressed men: randomized, placebo-controlled clinical trial. J Sex Marital Ther. 2006 May;32(3):267–73. [PubMed: 16809253]
329.
Gomaa AA, Hamed HA. Improvement of sexual function in partial testosterone-deficient ageing men treated with cream containing testosterone and vasoactive agents. J Mens Health Gend. 2006;3(1):47–55.
330.
Merza Z, Blumsohn A, Mah PM. et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Int J Androl. 2006 Jun;29(3):381–91. [PubMed: 16390499]
331.
Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology. 2006 Aug;68(2):386–91. [PubMed: 16904458]
332.
Knoll LD, Abrams JH. Nocturnal electrobioimpedance volumetric assessment of patients with erectile dysfunction. Urology. 1999 Jun;53(6):1200–4. [PubMed: 10367852]
333.
Hatzichristou DG, Apostolidis A, Tzortzis V. et al. Effects of oral phentolamine, taken before sleep, on nocturnal erectile activity: a double-blind, placebo-controlled, crossover study. Int J Impot Res. 2001 Oct;13(5):303–8. [PubMed: 11890519]
334.
Mann K, Pankok J, Leissner J. et al. Effects of moclobemide on sexual performance and nocturnal erections in psychogenic erectile dysfunction. Psychopharmacology. 2001 Jun;156(1):86–91. [PubMed: 11465638]
335.
Safarinejad MR. Therapeutic effects of high-dose isoxsuprine in the management of mixed-type impotence. Urology. 2001 Jul;58(1):95–7. [PubMed: 11445487]
336.
Enzlin P, Vanderschueren D, Bonte L. et al. Trazodone: a double-blind, placebo-controlled, randomized study of its effects in patients with erectile dysfunction without major organic findings. Int J Impot Res. 2000 Aug;12(4):223–8. [PubMed: 11079363]
337.
Costabile RA, Spevak M. Oral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo controlled trial. J Urol. 1999 Jun;161(6):1819–22. [PubMed: 10332444]
338.
Becker AJ, Stief CG, Machtens S. et al. Oral phentolamine as treatment for erectile dysfunction. J Urol. 1998 Apr;159(4):1214–6. [PubMed: 9507837]
339.
Meinhardt W, Schmitz PI, Kropman RF. et al. Trazodone, a double blind trial for treatment of erectile dysfunction. Int J Impot Res. 1997 Sep;9(3):163–5. [PubMed: 9315494]
340.
Peskircioglu L, Karabulut A, Deniz E. et al. The role of pentoxifylline in the treatment of erectile dysfunction due to borderline arterial insufficiency. Br J Urol. 1996 Apr;77(4):563–5. [PubMed: 8777618]
341.
Aydin S, Odabas O, Ercan M. et al. Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. Br J Urol. 1996 Feb;77(2):256–60. [PubMed: 8800895]
342.
van Ahlen H, Piechota HJ, Kias HJ. et al. Opiate antagonists in erectile dysfunction: a possible new treatment option? Results of a pilot study with naltrexone. Eur Urol. 1995;28(3):246–50. [PubMed: 8536780]
343.
Georgitis WJ, Merenich JA. Trial of pentoxifylline for diabetic impotence. Diabetes Care. 1995 Mar;18(3):345–52. [PubMed: 7555478]
344.
Kurt U, Ozkardes H, Altug U. et al. The efficacy of anti-serotoninergic agents in the treatment of erectile dysfunction. J Urol. 1994 Aug;152(2 Pt 1):t-9. [PubMed: 8015082]
345.
Korenman SG, Viosca SP. Treatment of vasculogenic sexual dysfunction with pentoxifylline. J Am Geriatr Soc. 1993 Apr;41(4):363–6. [PubMed: 8463520]
346.
Speel TGW, Kiemeney LA, Thien T. et al. Long-term effect of inhibition of the angiotensin-converting enzyme (ACE) on cavernosal perfusion in men with atherosclerotic erectile dysfunction: A pilot study. J Sex Med. 2005;2(2):207–12. [PubMed: 16422888]
347.
Piha J, Kaaja R. Effects of moxonidine and metoprolol in penile circulation in hypertensive men with erectile dysfunction: Results of a pilot study. Int J Impot Res. 2003;15(4):287–9. [PubMed: 12934058]
348.
Reiter WJ, Pycha A, Schatzl G. et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology. 1999 Mar;53(3):590–4. [PubMed: 10096389]
349.
Korenman SG, Viosca SP. Treatment of vasculogenic sexual dysfunction with pentoxifylline. J Age Rel Dis. 1994;6(3):24–8.
350.
Nickel M, Moleda D, Loew T. et al. Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study. Int J Impot Res. 2007 Jan;19(1):104–7. [PubMed: 16728967]
351.
Agostini R, Rossi F, Pajalich R. Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled study. Eur Rev Med Pharmacol Sci. 2006 Sep;10(5):247–50. [PubMed: 17121317]
352.
El-Shafey H, Atteya A, el-Magd SA. et al. Tianeptine can be effective in men with depression and erectile dysfunction. J Sex Med. 2006 Sep;3(5):910–7. [PubMed: 16942535]
353.
Sommer F, Klotz T, Steinritz D. et al. Evaluation of tetrahydrobiopterin (BH4) as a potential therapeutic agent to treat erectile dysfunction. Asian J Androl. 2006 Mar;8(2):159–67. [PubMed: 16491266]
354.
Akash R, Hrishikesh D, Amith P. et al. Case report: association of combined nonarteritic anterior ischemic optic neuropathy (NAION) and obstruction of cilioretinal artery with overdose of Viagra. J Ocul Pharmacol Ther. 2005 Aug;21(4):315–7. [PubMed: 16117695]
355.
Cunningham AV, Smith KH. Anterior ischemic optic neuropathy associated with viagra. J Neuroophthalmol. 2001 Mar;21(1):22–5. [PubMed: 11315976]
356.
Dheer S, Rekhi GS, Merlyn S. Sildenafil associated anterior ischaemic optic neuropathy. J Assoc Physicians India. 2002 Feb;50:265. [PubMed: 12038660]
357.
Egan R, Pomeranz H. Sildenafil (Viagra) associated anterior ischemic optic neuropathy. Arch Ophthalmol. 2000 Feb;118(2):291–2. [PubMed: 10676804]
358.
Gedik S, Yilmaz G, Akova YA. Sildenafil-associated consecutive nonarteritic anterior ischaemic optic neuropathy, cilioretinal artery occlusion, and central retinal vein occlusion in a haemodialysis patient [27] Eye. 2007;21(1):129–30. [PubMed: 16732206]
359.
Gruhn N, Fledelius HC. Unilateral optic neuropathy associated with sildenafil intake. Acta Ophthalmol Scand. 2005 Feb;83(1):131–2. [PubMed: 15715581]
360.
Margo CE, French DD. Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors. Am J Ophthalmol. 2007 Mar;143(3):538–9. [PubMed: 17317413]
361.
Pomeranz HD, Smith KH, Hart WM Jr. et al. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy.[see comment] Ophthalmology. 2002 Mar;109(3):584–7. [PubMed: 11874765]
362.
Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases.[see comment] J Neuroophthalmol. 2005 Mar;25(1):9–13. [PubMed: 15756125]
363.
Sinha S, Pathak-Ray V, Ahluwalia H. et al. Viagra or what? Eye. 2004 Apr;18(4):446–8. [PubMed: 15069453]
364.
Porst H, Buvat J, Meuleman E. et al. Intracavernous Alprostadil Alfadex—an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impot Res. 1998 Dec;10(4):225–31. [PubMed: 9884918]
365.
Canale D, Giorgi PM, Lencioni R. et al. Long-term intracavernous self-injection with prostaglandin E1 for the treatment of erectile dysfunction. Int J Androl. 1996;19(1):28–32. [PubMed: 8698535]
366.
Perimenis P, Konstantinopoulos A, Perimeni PP. et al. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J Androl. 2006 Mar;8(2):219–24. [PubMed: 16491275]
367.
Claro JA, de Aboim JE, Maringolo M. et al. Intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: an observational study. Sao Paulo Med J. 2001 Jul 5;119(4):135–7. [PubMed: 11500786]
368.
Lepore G, Nosari I. Efficacy of oral sildenafil in the treatment of erectile dysfunction in diabetic men with positive response to intracavernosal injection of alprostadil. Diabetes Care. 2001 Feb;24(2):409–11. [PubMed: 11213904]
369.
Perimenis P, Gyftopoulos K, Athanasopoulos A. et al. Diabetic impotence treated by intracavernosal injections: high treatment compliance and increasing dosage of vaso-active drugs. Eur Urol. 2001 Oct;40(4):398–402. [PubMed: 11713393]
370.
Wespes E, Sattar AA, Noel JC. et al. Does prostaglandin E1 therapy modify the intracavernous musculature? J Urol. 2000 Feb;163(2):464–6. [PubMed: 10647655]
371.
Shmueli J, Israilov S, Segenreich E. et al. Progressive treatment of erectile dysfunction with intracorporeal injections of different combinations of vasoactive agents. Int J Impot Res. 1999 Feb;11(1):15–9. [PubMed: 10098948]
372.
Chew KK, Stuckey BGA, Earle CM. et al. Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction. Int J Impot Res. 1997;9(4):225–30. [PubMed: 9442421]
373.
Sundaram CP, Thomas W, Pryor LE. et al. Long-term follow-up of patients receiving injection therapy for erectile dysfunction. Urology. 1997 Jun;49(6):932–5. [PubMed: 9187703]
374.
Gupta R, Kirschen J, Barrow RC. et al. Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol. 1997 May;157(5):1681–6. [PubMed: 9112505]
375.
Chen RN, Lakin MM, Montague DK. et al. Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis. J Urol. 1996 Jan;155(1):138–40. [PubMed: 7490812]
376.
Hattat H, Ozkara H, Akkus E. et al. Our experience with pharmacological erection treatment of erectile dysfunction. J Androl. 1994 Nov;15(Suppl):47S–9S. [PubMed: 7721677]
377.
Chiang HS, Wen TC, Wu CC. et al. Intracavernous self-injection therapy for the treatment of erectile dysfunction. J Formos Med Assoc. 1992;91(9):898–901. [PubMed: 1363391]
378.
Schramek P, Dorninger R, Waldhauser M. et al. Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism. Br J Urol. 1990 Jan;65(1):68–71. [PubMed: 2310934]
379.
Flynn RJ, Williams G. Long-term follow-up of patients with erectile dysfunction commenced on self injection with intracavernosal papaverine with or without phentolamine. Br J Urol. 1996 Oct;78(4):628–31. [PubMed: 8944522]
380.
Bolayir K, Goksin N. Intracavernous self-injection of papaverine and verapamil: a clinical experience. Acta Chir Hung. 1994;34(34):253–6. [PubMed: 7618376]
381.
Betts CD, Jones SJ, Fowler CG. et al. Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. Brain. 1994 Dec;117(Pt 6):1303–10. [PubMed: 7820567]
382.
Kerfoot WW, Carson CC. Pharmacologically induced erections among geriatric men. J Urol. 1991 Oct;146(4):1022–4. [PubMed: 1895417]
383.
Althof SE, Turner LA, Levine SB. et al. Sexual, psychological, and marital impact of self-injection of papaverine and phentolamine: A long-term prospective study. J Sex Marital Ther. 1991;17(2):101–12. [PubMed: 1920466]
384.
Fink HA, Mac DR, Rutks IR. et al. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2002 Jun 24;162(12):1349–60. [PubMed: 12076233]
385.
Montorsi F, McCullough A. Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: A systematic review of clinical data. J Sex Med. 2005;2(5):658–67. [PubMed: 16422824]
386.
Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. [Review][49 refs]. Cochrane Database Syst Rev 2007;(1):CD002187. [PubMed: 17253475]
387.
Montague DK, Jarow J, Broderick GA. et al. AUA guideline on the pharmacologic management of premature ejaculation. J Urol. 2004 Jul;172(1):290–4. [PubMed: 15201797]
388.
Wespes E, Amar E, Hatzichristou D. et al. Guidelines on erectile dysfunction. Eur Urol. 2002;41(1):1–5. [PubMed: 11999460]
389.
Heaton JPW, Morales A. Hormonal evaluation and treatment in male sexual function: A guide to clinical mangement. In: Mulcahy J, editors. 2nd New Jersey: Humana; 2008. p. 123–33.
390.
Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res. 2002 Feb;14(Suppl 1):S57–S64. [PubMed: 11850737]
391.
Anonymous. [Sildenafil Citrate (Viagra) - package insert]. 2002; U.S.A.: New York: Pfizer, Inc.
392.
Bella AJ, Brock GB. Intracavernous pharmacotherapy for erectile dysfunction. Endocrine. 2004;23(23):149–55. [PubMed: 15146094]
393.
El-Sakka AI. Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction. Int J Impot Res. 2006 Mar;18(2):180–5. [PubMed: 16163370]
394.
Melman A, Serels S, Morales et al. Priapism. Int J Impot Res. 2000;12(SUPPL. 4):S133–S139. [PubMed: 11035401]
395.
Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001 Apr 17;134(8):657–62. [PubMed: 11304106]
396.
Swerdloff RS, Wang C. Androgens and the ageing male. Best Practice & Research Clinical Endocrinology & Metabolism. 2004;18(3):349–62. [PubMed: 15261842]
Cover of Diagnosis and Treatment of Erectile Dysfunction
Diagnosis and Treatment of Erectile Dysfunction.
Evidence Reports/Technology Assessments, No. 171.
Tsertsvadze A, Yazdi F, Fink HA, et al.

AHRQ (US Agency for Healthcare Research and Quality)

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...